Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Time to Buy?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares shot up 4.1% during trading on Wednesday . The stock traded as high as $105.77 and last traded at $104.40. 18,274 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 139,152 shares. The stock had previously closed at $100.27.

Analysts Set New Price Targets

Several brokerages recently weighed in on PVLA. Craig Hallum began coverage on Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 target price for the company. Raymond James Financial reissued a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Cantor Fitzgerald raised their target price on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Chardan Capital lifted their target price on shares of Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $155.60.

Palvella Therapeutics Stock Up 5.5%

The firm’s fifty day moving average is $87.00 and its two-hundred day moving average is $58.77. The firm has a market cap of $1.25 billion, a P/E ratio of -40.23 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). As a group, sell-side analysts forecast that Palvella Therapeutics, Inc. will post -3.69 EPS for the current year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total value of $415,013.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 20.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently bought and sold shares of the business. Summit Partners Public Asset Management LLC purchased a new position in shares of Palvella Therapeutics during the third quarter valued at approximately $2,188,000. Mariner LLC purchased a new stake in shares of Palvella Therapeutics in the 3rd quarter worth approximately $1,299,000. Fred Alger Management LLC increased its position in Palvella Therapeutics by 1,279.1% during the 3rd quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock valued at $11,707,000 after buying an additional 173,209 shares in the last quarter. First Light Asset Management LLC purchased a new position in Palvella Therapeutics during the third quarter valued at $33,949,000. Finally, Bank of America Corp DE raised its stake in Palvella Therapeutics by 12.3% during the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after buying an additional 515 shares during the last quarter. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.